IBER
Ibere Pharmaceuticals
IBER
IBER
Delisted
IBER was delisted on the 1st of March, 2023.
48 hedge funds and large institutions have $105M invested in Ibere Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
48
Holders Change
+1
Holders Change %
+2.13%
% of All Funds
0.76%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
%
% of All Funds
0.02%
New
7
Increased
4
Reduced
7
Closed
6
Calls
$23K
Puts
–
Net Calls
+$23K
Net Calls Change
-$91K
Top Buyers
| 1 |
KC
Kryger Capital
London,
United Kingdom
|
+$4.14M |
| 2 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$3.43M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$3.14M |
| 4 |
CCM
Context Capital Management
Lajolla,
California
|
+$1.13M |
| 5 |
SCM
Saba Capital Management
New York
|
+$785K |
Top Sellers
| 1 |
D.E. Shaw & Co
New York
|
-$2.27M |
| 2 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$1.94M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$1.62M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.31M |
| 5 |
HIH
HRS Investment Holdings
New York
|
-$1.09M |